Why de novo sequencing still matters in proteomics
In short: if the database can’t tell you the answer, de novo might
Key learning points:
Jeremy has extensive knowledge of peptide and protein analysis and quantification from previous roles as a scientific officer and proteomics manager. He is experienced in processing a variety of sample matrices ranging from cancer-related matrices to those for infectious diseases covering the study of exosomes, parasites, venoms and lately immunology. Mass spectrometry has always been an essential part of Jeremy's career and with SCIEX as a Field Application Specialist. He applies his knowledge to provide support and guidance for the numerous SCIEX technology users in Australia and New Zealand (ANZ).
The webinar is over. The on-demand version will be available soon.